The Behnke Group is proud to support Cizzle Bio, Inc.’s latest initiative to improve lung cancer detection through a significant new collaboration with Moffitt Cancer Center, a leading cancer research and treatment institution based in Florida. This partnership marks a pivotal moment in the advancement of innovative diagnostic solutions aimed at early-stage lung cancer detection.
Collaboration Overview:
Cizzle Bio, Inc., a leader in developing biomarker-based diagnostic tools for early cancer detection, has partnered with Moffitt Cancer Center to clinically evaluate the effectiveness of its CIZ1B biomarker test in identifying early-stage lung cancer in patients with suspicious lung nodules. This marks the first large-scale clinical setting where the CIZ1B biomarker will be tested to distinguish between cancerous and non-cancerous nodules.
Key Aspects of the Collaboration:
-
Clinical Evaluation with Moffitt Cancer Center
Moffitt’s prestigious lung cancer screening program will assess the performance of the CIZ1B biomarker test to provide new insights into its potential to enhance early detection.
-
Innovative Use of New Monoclonal Antibodies
The evaluation will utilize newly developed monoclonal antibodies produced in collaboration with BBI Solutions to boost the test’s sensitivity and specificity.
-
Paving the Way for Future Partnerships
This collaboration lays the groundwork for further clinical partnerships with major cancer centers across the United States, aiming to make the CIZ1B test widely available to clinicians.
Why This Matters:
Early detection of lung cancer remains a critical challenge in the fight against the disease, with a significant impact on patient outcomes. The CIZ1B biomarker test, if validated through this study, could provide a more accurate, cost-effective diagnostic tool to complement existing screening methods, reduce false positives, and improve early diagnosis rates. The Behnke Group is pleased to see this step forward in developing advanced solutions that could save lives and improve cancer care globally.
What’s Next:
The collaboration with Moffitt Cancer Center is only the beginning. With plans to expand the use of the CIZ1B biomarker test across multiple major cancer centers and clinics throughout the United States, Cizzle Bio, Inc. continues to lead the way in innovative cancer diagnostics.
Stay tuned for more updates on this important development and learn more about how The Behnke Group supports groundbreaking initiatives in biotechnology and healthcare innovation.
Learn more on Cizzle Bio, Inc.’s website: https://www.cizzlebio.com/news/cizzle-bio-inc-partners-with-moffitt-cancer-center